Tripodi Beniamino, Matarese Irene, Carbone Manuel Glauco
Department of Mental Health and Addictions, Division of Psychiatry, ASST Crema, Via Largo Ugo Dossena 2, 26013 Crema, Italy.
Pisa-School of Experimental and Clinical Psychiatry, University of Pisa, Via Roma 57, 56100 Pisa, Italy.
Life (Basel). 2023 Jan 20;13(2):293. doi: 10.3390/life13020293.
(1) Background: To systematically review evidence on the safety and efficacy of psychopharmacological treatments available for psychomotor agitation (PA) in children and adolescents. (2) Methods: Studies assessing the safety and efficacy of psychopharmacological treatments for acute PA in children and adolescents that were published between January 1984 and June 2022 on PubMed were systematically reviewed. We included: (i) papers that presented a combination of the search terms specified in the "" sub-paragraph; (ii) manuscripts in English; (iii) original papers; (iv) prospective or retrospective/observational studies and experimental or quasi-experimental reports. The exclusion criteria were: (i) review papers; (ii) non-original studies including editorials and book reviews; (iii) studies not specifically designed and focused on the selected topic. (3) Results: We selected 42 papers: 11 case series (11/42, 26.19%), 8 chart reviews (8/42, 19.05%), 8 case reports (8/42, 19.05%), 6 double-blind placebo-controlled randomized studies (6/42, 14.29%), 4 double-blind controlled randomized studies (4/42, 9.52%), 4 open-label trials (4/42, 9.52%) and 1 case control (1/42, 2.38%). (4) Conclusions: The drugs most frequently used to treat agitation in children and adolescents were ziprasidone, risperidone, aripiprazole, olanzapine and valproic acid. Further studies are needed to evaluate the efficacy/safety ratio, considering the limited number of observations in this field.
(1) 背景：系统评价可用于治疗儿童和青少年精神运动性激越（PA）的精神药物治疗的安全性和有效性证据。(2) 方法：系统回顾1984年1月至2022年6月在PubMed上发表的评估儿童和青少年急性PA精神药物治疗安全性和有效性的研究。我们纳入：(i) 呈现“”子段落中指定搜索词组合的论文；(ii) 英文手稿；(iii) 原创论文；(iv) 前瞻性或回顾性/观察性研究以及实验性或准实验性报告。排除标准为：(i) 综述论文；(ii) 非原创研究，包括社论和书评；(iii) 未专门设计和聚焦于所选主题的研究。(3) 结果：我们筛选出42篇论文：11篇病例系列（11/42，26.19%）、8篇图表回顾（8/42，19.05%）、8篇病例报告（8/42，19.05%）、6篇双盲安慰剂对照随机研究（6/42，14.29%）、4篇双盲对照随机研究（4/42，9.52%）、4篇开放标签试验（4/42，9.52%）和1篇病例对照（1/42，2.38%）。(4) 结论：用于治疗儿童和青少年激越最常用的药物是齐拉西酮、利培酮、阿立哌唑、奥氮平和丙戊酸。鉴于该领域观察数量有限，需要进一步研究以评估疗效/安全性比。
